Insights

Benchmark International het suksesvol die transaksie tussen Triducive Partners Ltd en Bioscript Group Limited gefasiliteer.

May 26, 2026

Benchmark International is verheug om die transaksie tussen Triducive en Bioscript aan te kondig.

Gestig in 2009 en gebaseer in St Albans, Hertfordshire, werk Triducive saam met baie van die wêreld se voorste farmaseutiese maatskappye, insluitend AstraZeneca en Johnson & Johnson. Mede-oprichters Tim Warren en Nick Williams sal by die besigheid bly en sodoende kontinuïteit vir kliënte verseker terwyl Triducive in Bioscript se Data- en Insights-afdeling geïntegreer word.

Bioscript is 'n spesialisgesondheidsorgkommunikasie- en wetenskaplike dienstegroep wat deur Sovereign Capital Partners ondersteun word.

Triducive is die vyfde oorname wat deur Bioscript voltooi is sedert Sovereign in 2021 in die besigheid belê het. Die toevoeging versterk verder Bioscript se vermoë om kliënte oor die volle mediese sake-waardeketting te ondersteun, van bewysegenerering tot publikasie, adviesrade en wetenskaplike kommunikasie.

Skeduleer 'n vertroulike konsultasie.

Tim Warren, besturende vennoot van Triducive, het gesê: "Om by Bioscript Group aan te sluit, gee ons die platform om die impak van ons werk te verbreed. Die vermoë om ons insiggenerering met Bioscript se kommunikasie-kundigheid te kombineer, sal kliënte in staat stel om bewyse meer effektief en met groter bereik in aksie om te sit. Die ooreenstemming van waardes en ambisie maak dit 'n opwindende vennootskap vir ons span en ons kliënte."

Gabrielle Silver, hoof uitvoerende beampte by Bioscript, het gesê: "Triducive bring uitsonderlike sterkte mee in die generering van die soort gestruktureerde,praktykgebaseerde insigte wat kliënte help om te verstaan wat werklik kliniese en beleidsbesluite beïnvloed. Deur dit te kombineer met Bioscript se strategiese kommunikasie-kundigheid, kan ons kliënte ondersteun met programme wat gegrond is op werklike wêreldervaring."

Dominic Dalli, besturende vennoot by Sovereign, het gesê: "Triducive is 'n hoëgehalte-aanvulling wat Bioscript se aanbod betekenisvol versterk. Hul kundigheid in die destilleer van kundige kliniese konsensus lê aan die begin van die mediese sake-waardeketting, en deur dit met Bioscript se kommunikasieplatform te kombineer, skep dit 'n oortuigende, geïntegreerde aanbod vir kliënte."

Beplan 'n oproep

Americas: Sam Smoot at +1 (813) 898 2350 / [email protected]

Europe: Michael Lawrie at +44 (0) 161 359 4400 / [email protected]

Africa: Anthony McCardle at +27 21 300 2055 / [email protected] 

 

ABOUT BENCHMARK INTERNATIONAL:

Benchmark International is a global M&A firm that provides business owners with creative, value-maximizing solutions for growing and exiting their businesses. Benchmark International has handled transactions across various industries from offices across the world. With decades of M&A experience, Benchmark International’s transaction teams have assisted business owners with achieving their objectives and ensuring the continued growth of their businesses. The firm has also been named the Investment Banking Firm of the Year by The M&A Advisor and the Global M&A Network, as well as the #1 Sell-side Privately Owned M&A Advisor in the World by PitchBook’s and LSEG's Global League Tables.

The content provided by Benchmark International, including articles, blog posts, videos, and other media, is for general informational purposes only and does not constitute legal, financial, investment, or business advice. While we strive for accuracy, the information may be based on third-party sources, market trends, and evolving industry data that are not independently verified or guaranteed to be current or complete. Any opinions expressed are those of the authors and do not necessarily reflect the views of Benchmark International. Market trends, forecasts, and forward-looking statements are inherently uncertain and subject to change. Nothing in our content should be relied upon as a substitute for personalized advice from qualified professionals. Benchmark International disclaims all liability for any loss or damage resulting from reliance on this content. Always consult with appropriate experts before making business decisions.

Share This Post
Categories

Get These Insights Delivered Directly To Your Email

Explore our curated collection today and stay ahead of the curve in M&A.

Related Posts
How to Attract the Right Buyers: What Makes a Business More ValuableIn the dynamic world of mergers and acquisitions (M&A), selling your business is a complex process that requires strategic planning, valuation expertise, and an understanding of what potential buyers are looking for. Buyers and investors are driven by various motives, including growth acceleration, market expansion, and portfolio diversification. Successfully attracting the right buyers can significantly impact the sale price and the overall success of the transaction. But what exactly can make your business more valuable and appealing to prospective buyers? Let’s explore the key factors that may enhance your company's attractiveness in M&A and how you can position your business for maximum appeal.Why Multi-Party Sale Processes Are an Opportunity for BuyersTo many acquirers, the words “competitive process” still carry an undertone of friction. They suggest distraction, inflated expectations, unnecessary pressure, and the risk of being used as a price tension rather than a serious counterparty. Yet this interpretation often misses the deeper reality. For most business owners, particularly founders and long-tenured operators, a multi-party sale process is not an act of aggression; it is an act of responsibility – to themselves, to the business, and to the buyer.
Not Finding What You're Looking For?
Ready to dive into our featured M&A content and gain valuable insights for your business?